Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade

Quentin Lecocq¹, Robin Maximilian Awad¹, Yannick De Vlaeminck¹, Wout de Mey¹, Thomas Ertveldt¹, Cleo Goyvaerts¹, Geert Raes²,³, Kris Thielemans¹, Marleen Keyaerts⁴,⁵, Nick Devoogdt*¹, and Karine Breckpot*¹

¹Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium; ²Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, Brussels, Belgium; ³Unit of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; ⁴In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussels, Brussels, Belgium; and ⁵Nuclear Medicine Department, UZ Brussel, Brussels, Belgium

Recent advances in the field of immune-oncology led to the discovery of next-generation immune checkpoints (ICPs). Lymphocyte activation gene-3 (LAG-3), being the most widely studied among them, is being explored as a target for the treatment of cancer patients. Several antagonistic anti-LAG-3 antibodies are being developed and are prime candidates for clinical application. Furthermore, validated therapies targeting cytotoxic T-lymphocyte-associated protein-4, programmed cell-death protein-1, or programmed cell-death ligand-1 showed that only subsets of patients respond. This finding highlights the need for better tools for patient selection and monitoring. The potential of molecular imaging to detect ICPs noninvasively in cancer is supported by several preclinical and clinical studies. Here, we report on a single-domain antibody to evaluate whole-body LAG-3 expression in various syngeneic mouse cancer models using nuclear imaging. Methods: SPECT/CT scans of tumor-bearing mice were performed 1 h after injection with radiolabeled single-domain antibody. Organs and tumors of mice were isolated and evaluated for the presence of the radiolabeled tracer and LAG-3-expressing immune cells using a γ-counter and flow cytometry respectively. PD-1/LAG-3-blocking antibodies were injected in MC38-bearing mice. Results: The radiolabeled single-domain antibody detected LAG-3 expression on tumor-infiltrating lymphocytes (TILs) as soon as 1 h after injection in MC38, MO4, and TC-1 cancer models. The single-domain antibody tracer visualized a compensatory upregulation of LAG-3 on TILs in MC38 tumors of mice treated with PD-1-blocking antibodies. When PD-1 blockade was combined with LAG-3 blockade, a synergistic effect on tumor growth delay was observed. Conclusion: These findings consolidate LAG-3 as a next-generation ICP and support the use of single-domain antibodies as tools to noninvasively monitor the dynamic evolution of LAG-3 expression by TILs, which could be exploited to predict therapy outcome.

Key Words: cancer; nuclear imaging; single domain antibody; Nanobody; immune checkpoint; LAG-3

Received Oct. 20, 2020; revision accepted Feb. 3, 2021.
For correspondence or reprints, contact Nick Devoogdt (nick.devoogdt@vub.be) or Karine Breckpot (karine.breckpot@vub.be).
Published online March 12, 2021.
Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.
©COPYRIGHT 2021 by the Society of Nuclear Medicine and Molecular Imaging.
margin was determined using immunohistochemistry. It was observed that the objective response rate almost doubled in the LAG-3 expression group, underscoring the need for patient stratification.

Immunohistochemistry has several limitations with respect to ICP detection and subsequent patient selection (18,19). The need for a biopsy, the heterogeneous and dynamic expression of ICPs within the TME, and their role outside the TME are factors that can lead to incorrect stratification of patients. This could, for instance, explain why patients with undetectable PD-L1 levels showed beneficial effects of PD-L1 blockade (20). As opposed to immunohistochemistry, nuclear imaging is a noninvasive process that can be performed repeatedly irrespective of the tumor location (18,19,27). For example, imaging of PD-1 or PD-L1 using PET tracers has been performed in clinical trials, showing a better correlation with therapy outcome than immunohistochemistry (22,23). For the sake of safety and clinical practicality, nuclear imaging should be fast and generate high-contrast images, which can be achieved with small, stable, and soluble antigen-binding moieties.

Single-domain antibodies, the smallest antigen-binding fragment of camelid heavy-chain-only antibodies, are excellent tools to target proteins in the TME (18,19). Single-domain antibodies are small and easy to engineer and produce. Several radiolabeled single-domain antibodies are currently being evaluated in the clinic, including a 99mTc-radiolabeled single-domain antibody that targets PD-L1, showing specific uptake in patients with non-small cell lung carcinoma at 2 h after injection (24–27). Therefore, single-domain antibody targeting LAG-3 could be interesting diagnostic tools for noninvasive detection of LAG-3 before and after ICP treatment.

We previously reported the characterization of single-domain antibodies that target mouse LAG-3, showing that 99mTc-labeled single-domain antibody 3132 is an excellent SPECT probe to specifically detect LAG-3 on immune cells and on tumor cells that were engineered to express high levels of LAG-3 (28). In this study, we assessed the ability of this single-domain antibody to image LAG-3 on tumor-infiltrating lymphocytes (TILs) in different mouse cancer models by SPECT/CT. We show that this single-domain antibody can accurately quantify LAG-3 levels in the TIL compartment. We moreover demonstrate the ability to detect LAG-3 upregulation on TILs in MC38 tumors of mice that were treated with anti-PD-1 mAbs. The enhanced therapy outcome in MC38-bearing mice treated with mAbs blocking PD-1 and LAG-3 corroborates the upregulation of LAG-3, as observed by nuclear imaging with the LAG-3 single-domain antibody.

MATERIALS AND METHODS
Mice, Cell Lines, and Reagents
Female, C57BL/6 mice (6–12 wk old) were purchased from Charles River. The institution’s ethical committee for use of laboratory animals approved the experiments. These were performed following the European guidelines for animal experimentation. MC38 mouse colorectal cancer cells and human embryonic kidney 293T cells were obtained from ATCC. MO4 melanoma cells were provided by Kenneth Rock (University of Massachusetts Medical School). These cells were cultured in Dulbecco modified Eagle’s medium supplemented with 10% fetal bovine serum (Tico Europe), 2 mM L-glutamine, and 100 U/mL penicillin with 100 μg/mL streptomycin. The TC-1 mouse lung cancer cells were provided by Trzy-Chou Wu (Johns Hopkins University) and cultured in RPMI1640 medium, supplemented with 10% fetal clone 1 serum (Thermo Fisher Scientific), L-glutamine, 100 U/mL penicillin with 100 μg/mL streptomycin, 1 mM sodium pyruvate with nonessential amino acids, 12.5 mM D-glucose, 5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, and 50 μM β-mercaptoethanol. Culture media and supplements were from Sigma-Aldrich unless noted otherwise. A LAG-3–specific PerCP-eFluor710 or phycoerythrin-labeled antibody (clone eBioC9B7W; Biolegend) was used in flow cytometry. Antibodies from BD Biosciences were used to discriminate immune cells in flow cytometry: CD45.2-APC-Cy7 (clone 104), CD4-AF700 (clone RM4-5), CD8-V450 (clone 53-67), CD19-AF647 (clone 1D3), and F4/80-BB700 (clone T452342).

Single-Domain Antibody Production and Quality Control
The LAG-3 single-domain antibody 3132 was selected from a panel of candidates for its ability to bind to mouse LAG-3 (28). Single-domain antibody R3B23, binding a multiple myeloma paraprotein (29), was used as a negative control. Single-domain antibody production and quality control were performed as previously described (28).

Inoculation of Tumor Cells and Monitoring of Tumor Growth
Mice were subcutaneously injected with 3 × 106 MC38, MO4, or TC-1 cells. Body weight, behavior, physical appearance, and tumor ulceration were examined daily. Tumor dimensions were measured every other day using a caliper to calculate the tumor volume: (length × width2)/2. All procedures were performed under isoflurane anesthesia (5% for induction and 2.5% for maintenance, with an oxygen flow of 1 L/min).

ICP Blockade in Tumor-Bearing Mice
MC38-bearing mice were injected intraperitoneally with 10 mg/kg Ultra-LEAF mAbs (Biolegend) targeting mouse PD-1 (clone RPM1-14), mouse LAG-3 (clone C9B7W), an isotope-matched control (IC) for the PD-1 monotherapy (rat IgG2a, clone RTK2758), or a mixture of IC mAbs for the anti-PD-1/LAG-3 combination therapy (rat IgG1, clone RTK2071, and rat IgG2a, clone RTK2758).

Single-Domain Antibody 99mTc Labeling, SPECT/CT Imaging, Image Analysis, and Biodistribution Analysis
One hour before pinhole SPECT/small-animal CT imaging, the mice were intravenously injected with 5 μg of 99mTc-labeled LAG-3 or control single-domain antibody, with, on average, 68.8 ± 6.8 MBq and 88.9 ± 5.1 MBq of injected activity, respectively. SPECT/CT imaging was performed using a VECToR SPECT/CT scanner (MILabs). SPECT imaging was performed with a 1.5-mm 75-pinhole general-purpose collimator, in spiral mode with 6 bed positions. The SPECT scan time for the total body was 15 min, 150 s per position. The CT scan time was 139 s in total, set to 60 kV and 615 mA. During all imaging procedures, the mice were anesthetized by intraperitoneal injection with 75 mg/kg ketamine and 1 mg/kg medetomidine (Ketamid; Richter Pharma AG). Immediately after imaging, the organs of the killed mice were isolated and weighed. The submandibular lymph nodes were selected as representative lymph nodes. The organ-specific uptake of each radiotracer was measured using a Wizard3 γ-counter (PerkinElmer). The uptake in each organ was corrected for decay and calculated as the percentage of injected activity per gram (%IA/g). Image analysis was performed using AMIDE (Medical Image Data Examiner software) and HOROS medical imaging viewer (lesser general public license at https://horosproject.org/). Isolated organs were kept in MACS tissue storage solution (Miltenyi Biotec) when flow cytometry analysis was required.

Single-Cell Preparation of Tumor and Spleen
Single-cell suspensions of tumors and spleens were prepared according to protocols 130-096-730 and 130-095-926 of Miltenyi Biotec. The tumors were cut into approximately 3-mm pieces and transferred to gentleMACS C tubes containing 5 mL of ice-cold RPMI1640 supplemented with 1,000 U/mL DNase I and 100 μL of collagenase I. Tumors and whole spleens were homogenized at 37°C for, respectively, 45 and 15 min using the gentleMACS Octo Dissociator (programs cus_37C_mmlmpTu2 and 37C_m_SDK_1, respectively). The cell suspension was
Spearman correlation tests for calculated using Mann–Whitney tests and for the LAG-3 single-domain antibody tracer we observed signals in tumors (Fig. 1). After imaging, organs were dissected and weighed, and radioactivity levels were measured (Fig. 2A). Analysis of tumor uptake showed that only radiolabeled LAG-3 single-domain antibody accumulated in MC38 tumors, with little increase in larger tumors (P = 0.0364 and P = 0.0091 for day 11 and 17 tumors, respectively) (Fig. 2B). We assessed the accuracy of the radiolabeled single-domain antibodies to image LAG-3 expression levels in the tumor by comparing ex vivo γ-counts with the activity that can be measured on SPECT/CT scans using AMIDE software (Fig. 2C). LAG-3 single-domain antibody tumor uptake was also evaluated in mice bearing TC-1 or MO4 tumors. The average tumor size and the injected single-domain antibody doses are shown in Supplemental Figure 2A. Eighty minutes after injection, LAG-3 single-domain antibody accumulated in TC-1 and MO4 tumors (Supplemental Fig. 2B). Flow cytometry analysis showed LAG-3 expression on CD45+ immune cells in TC-1 or MO4 tumors (Supplemental Figs. 2C and 2D). In both models, tracer uptake levels and mean fluorescence intensity (MFI) of LAG3+ TILs correlated positively (Supplemental Fig. 2D). Representative axial images of both tumor types are shown in Supplemental Fig. 2E.

**RESULTS**

**Radiolabeled LAG-3 Single-Domain Antibodies Allow Imaging of LAG-3 in TME**

We radiolabeled LAG-3 or control single-domain antibodies with 99mTc and compared their biodistribution in MC38-bearing mice by performing SPECT/CT at days 11 or 17 of tumor growth (Supplemental Figs. 1A–1C; supplemental materials are available at http://jnm.snmjournals.org). The average injected dose and tumor size at the time of evaluation are shown in Supplemental Figure 1D. Eighty minutes after injection, we observed signals in kidneys and bladder due to single-domain antibody clearance, and for the LAG-3 single-domain antibody tracer we observed signals in tumors (Fig. 1). After imaging, organs were dissected and weighed, and radioactivity levels were measured (Fig. 2A). Analysis of tumor uptake showed that only radiolabeled LAG-3 single-domain antibody accumulated in MC38 tumors, with little increase in larger tumors (P = 0.0364 and P = 0.0091 for day 11 and 17 tumors, respectively) (Fig. 2B). We assessed the accuracy of the radiolabeled single-domain antibodies to image LAG-3 expression levels in the tumor by comparing ex vivo γ-counts with the activity that can be measured on SPECT/CT scans using AMIDE software (Fig. 2C). LAG-3 single-domain antibody tumor uptake was also evaluated in mice bearing TC-1 or MO4 tumors. The average tumor size and the injected single-domain antibody doses are shown in Supplemental Figure 2A. Eighty minutes after injection, LAG-3 single-domain antibody accumulated in TC-1 and MO4 tumors (Supplemental Fig. 2B). Flow cytometry analysis showed LAG-3 expression on CD45+ immune cells in TC-1 or MO4 tumors (Supplemental Figs. 2C and 2D). In both models, tracer uptake levels and mean fluorescence intensity (MFI) of LAG3+ TILs correlated positively (Supplemental Fig. 2D). Representative axial images of both tumor types are shown in Supplemental Fig. 2E.

**Biodistribution of radiolabeled LAG-3 and control single-domain antibodies in MC38-bearing mice at days 11 or 17 of tumor growth.** (A) Ex vivo γ-counting of isolated organs from MC38-bearing mice 80 min after injection of LAG-3 or control single-domain antibody tracers. (B) Individual tumor uptake levels of LAG-3 and control single-domain antibody tracers as determined by ex vivo γ-counting. (C) Correlation plot of tumor uptake within image region of interest (x-axis) and ex vivo γ-counting of tumors (y-axis) for LAG-3 single-domain antibody tracer. ROI = region of interest; sdAb = single-domain antibody.
PD-1 Blockade Causes Upregulation of LAG-3 on TILs

We evaluated whether we could detect LAG-3 upregulation on TILs during PD-1 blockade in the MC38 model (31,32). Tumor-bearing mice were treated with anti-PD-1 or control mAbs. SPECT/CT imaging and ex vivo validations after injection of $^{99m}$Tc-labeled LAG-3 single-domain antibody were performed (Supplemental Fig. 3A). We observed a slower tumor growth when mice were treated with PD-1–blocking mAbs than when they were treated with IC mAbs (Supplemental Figs. 3B and 4A; $P = 0.0323$). We further analyzed SPECT/CT images using quantification software (Fig. 3A) and calculated activity within the region of interest, assigned over the tumor mass. These values correlated positively with the $\gamma$-counts obtained through ex vivo analysis (Fig. 3B). Ex vivo biodistribution analysis showed a significantly higher uptake of LAG-3 single-domain antibody in lymph nodes ($P = 0.0037$) and MC38 tumors ($P = 0.0022$), but not in spleen, as a result of PD-1 blockade (Supplemental Figs. 4B–4E, 5A, and 5B). LAG-3 single-domain antibody tumor uptake in mice treated with anti-PD-1 or IC mAbs was also compared with the MFI of LAG-3 expression on TILs, measured in flow cytometry.

![Image](image_url)
A positive correlation was found for CD45+ total TILs, CD8+ T cells, CD19+ B cells, and F4/80+ macrophages but not for CD4+ T cells (Fig. 4A). We also observed a significantly higher CD8+ T-cell infiltration in tumors of PD-1–treated mice relative to IC (Fig. 4B; *P = 0.0350) but no differences in tumor infiltration for CD4+ T cells, CD19+ B cells, or F4/80+ macrophages (data not shown). Notably, we observed an increase in LAG-3 expression on total CD45+ TILs in mice treated with anti-PD-1 mAbs (*P = 0.0221) (Fig. 4C). Although not significantly different between PD-1–treated and IC–treated groups, the proportion of LAG-3+ CD8+ T cells (*P = 0.0518), CD19+ B cells (*P = 0.1807), and F4/80+ macrophages (*P = 0.1807) tended to be more pronounced in mice treated with anti-PD-1 mAbs (Fig. 4D). Elevated expression of LAG-3 on TILs in mice treated with anti-PD-1 mAbs was further corroborated by an increase in MFI, which was statistically different from the IC–treated group for CD19+ B cells (Fig. 5, *P = 0.0140). Interestingly, no significant difference in LAG-3 expression was observed on spleen-residing immune cells of the PD-1–treated and IC–treated groups (Fig. 5), as is in line with the spleen uptake values of radiolabeled LAG-3 single-domain antibody (Supplemental Fig. 4D).

**Blockade of LAG-3 in Combination with PD-1 Blockade Enhances Therapy Outcome**

We next assessed whether blockade of LAG-3 and PD-1 in the MC38 model prolonged the tumor growth delay. Tumor-bearing mice were treated with anti-PD-1 or anti-LAG-3 mAbs as shown in Figure 6. Mice treated with a mixture of IC mAbs served as a control. The delay in tumor growth on treatment with anti-LAG-3 mAbs alone was not significant, whereas a statistical difference was observed between anti-PD-1–treated and IC mAb–treated mice (Fig. 6; *P = 0.0201). Combined PD-1/LAG-3 blockade further delayed tumor growth when compared with IC mAbs (*P = 0.0001) or monotherapy with anti-LAG-3 (*P = 0.0201) or anti-PD-1 (*P = 0.5257) mAbs. This translated into a significantly longer time to reach humane endpoints in mice receiving the combination therapy than in mice treated with IC (*P = 0.0005), anti-LAG-3 (*P = 0.0004), or anti-PD-1 (*P = 0.0181) mAbs (Fig. 6).

**DISCUSSION**

mAbs targeting ICPs such as CTLA-4 and PD-1/PD-L1 have changed the field of immune-oncology because of their potent effects in a diversity of human cancers. However, there is still a fraction of patients who do not respond to this therapy. Additional ICPs such as LAG-3 have been discovered, offering the potential to overcome resistance in some of these patients by blocking LAG-3. Its important role in cancer development has been addressed in numerous preclinical studies (28,32–37). LAG-3 was shown to be expressed on T cells, B cells, plasmacytoid dendritic cells, natural killer cells, and macrophages (1,6,11,28). Its induction is related to the dysfunction of cancer-specific T cells often associated with PD-1 coexpression (33,34,38). The latter could be an explanation of therapeutic
resistance to single-agent ICP blockade in patients. Subsequently, efforts have been made to develop anti-LAG-3 mAbs and explore their anticancer efficacy when used alone or in combination with anti-PD-1 blockade.

Evaluating the expression of ICPs within the tumor to select patients and predict their therapy outcome is of interest. Nuclear imaging using small binding moieties such as single-domain antibodies is a method to quickly detect biomarkers with high contrast in a noninvasive way (18,21). Moreover, this method can be performed repeatedly in the same patient regardless of the location of the tumor. Several clinical studies led to the observation that radiolabeled single-domain antibodies are good candidates to detect tumor biomarkers with high contrast as soon as 60 min after administration to the patient (19,26,27,39).

To our knowledge, we were the first to report different single-domain antibodies targeting mouse LAG-3 and to select one of these single-domain antibodies for detection of LAG-3–engineered tumor cells (28). In this study, we evaluated this single-domain antibody for detection of LAG-3–expressing TILs. We performed SPECT/CT imaging on immunocompetent colon carcinoma–bearing mice using 99mTc-labeled LAG-3 single-domain antibody and compared tumor uptake values with a radiolabeled control single-domain antibody. Moreover, we performed imaging at days 11 or 17 of tumor growth to evaluate whether tumor size alters LAG-3 detection with the single-domain antibody tracer. Besides the specific signals detected in organs such as the thymus, spleen, and lymph nodes, we observed a significantly increased uptake of LAG-3 single-domain antibody in tumors compared with control single-domain antibody. No difference in single-domain antibody uptake was observed when comparing weight-corrected uptake values in the tumors imaged at days 11 or 17. The ex vivo measured tumor activities could be correlated to the SPECT/CT images. We further extended our SPECT/CT imaging studies and ex vivo validations to a syngeneic melanoma and lung cancer model. The LAG3 single-domain antibody tracer also accumulated in tumors expressing TILs. We performed SPECT/CT imaging of these tumors. Notably, uptake values correlated with the ex vivo–evaluated LAG-3 expression on CD45+ TILs using flow cytometry. Overall, the SPECT/CT images of these scans show the potency of the single-domain antibody tracer to map LAG-3 in the TME.

LAG-3 expression can act as a compensatory mechanism that leads to therapeutic resistance of PD-1 blockade in cancer patients (17,33,34,38). To our knowledge, we are the first to explore the effects of PD-1 treatment on LAG-3 expression and distribution using molecular imaging. MC38–bearing mice were treated with PD-1–blocking mAbs, leading to tumor growth impairment. Noninvasive imaging revealed elevated uptake of LAG-3 single-domain antibody tracer in tumor and lymph nodes relative to the IC treatment group. PD-1–treated mice had more CD8+ T cells in their tumor and more LAG-3+ TILs. A positive correlation was found between the amount of LAG-3 single-domain antibody tracer in the tumor and the LAG-3 levels on CD8+ T cells, CD19+ B cells, and F4/80+ macrophages. However, some individual samples were inconclusive when we attempted to correlate LAG-3 single-domain antibody uptake levels with flow cytometry data. Intriguingly, previous studies suggest that checkpoint blockade causes changes in the tumor environment such as a reduction in tumor interstitial pressure and decompressed tumor blood vessels (40). Although proven for PD-L1–blocking antibodies, we must not exclude the possibility of similar anti-PD-1–mediated modifications that can alter the exposure of tumors to our radiolabeled LAG-3 single-domain antibody tracer. Nevertheless, the proper correlation of LAG-3 single-domain antibody uptake levels with flow cytometry data could have been clarified by also analyzing tumors using immunohistochemistry, as it would have allowed us to more accurately quantify the percentage of immune cells per unit weight of tumor. Taken together, our findings support the idea of a compensatory upregulation of LAG-3 in the TME after PD-1 blockade. This compensatory LAG-3 expression in tumors on PD-1 treatment could be reliably captured with high contrast with the LAG-3 single-domain antibody SPECT/CT tracer.

Because we observed a compensatory upregulation of LAG-3 in the TME after single-agent PD-1 blockade, we evaluated the anticancer effects of combined LAG-3/PD-1 blockade in MC38 tumors. Tumor growth was marginally affected by LAG-3 blockade. However, when combined with PD-1 blockade, its anticancer effect surpasses the already significant decrease in tumor growth observed with PD-1 blockade. This corroborates the compensatory role of LAG-3 on PD-1 blockade in the MC38 model and underscores the benefit of combining blockade of multiple ICPs (31,32).

As an increasing number of clinical trials investigate LAG-3 blockade in immunotherapy, most often in combination with PD-1 blockade, a clinical tracer to monitor LAG-3 levels in the tumors of patients is also of high interest. This study used a single-domain antibody–binding mouse LAG-3 with no cross-reactivity with human LAG-3. We developed a single-domain antibody that binds to human LAG-3 with low-nanomolar affinity for human LAG-3 and a good capacity to visualize human LAG-3+ tumors in mice (Quentin Lecocq, unpublished data, August 2021). Optimally, this single-domain antibody needs to be labeled with a short-lived PET isotope such as 68Ga or 18F using new or established radiochemistry procedures (25,41–43). Extrapolating from our still-ongoing clinical trials with a 68Ga-labeled anti–human epidermal growth factor receptor 2 single-domain antibody breast cancer PET tracer (26) and an anti-CD206 single-domain antibody macrophage PET tracer (25), we are hopeful that the future clinical anti-LAG-3 single-domain antibody PET tracer will also be safe and sensitive and will conveniently provide a whole-body picture of LAG-3 expression levels in a same-day imaging procedure with acceptable dosimetry levels.

CONCLUSION

These findings consolidate LAG-3 as a next-generation ICP and support the use of single-domain antibodies as tools to noninvasively monitor the dynamic evolution of LAG-3 expression by TILs, which could be exploited to predict therapy outcome.

DISCLOSURE

This research was financially supported by the Belgian Foundation against Cancer, Kom op tegen Kanker (Stand Up to Cancer), the Flemish Cancer Society, and the Research Foundation Flanders (FWO-V; 1501019N and 1001618N). Quentin Lecocq has been funded via an “Emmanuel Vanderschueren” award and is an FWO-SB fellow (1IS24218N). Marleen Keyaerts received research funding from Precirix (formerly named Camel-IDS). Quentin Lecocq, Karine Breckpot, Nick Devoogdt, and Marleen Keyaerts have patents on the use of single-domain antibodies for imaging and therapy. Nick Devoogdt and Marleen Keyaerts have ownership in AbScint, which leverages single-domain antibody imaging tracers into clinical application. No other potential conflict of interest relevant to this article was reported.
ACKNOWLEDGMENTS

We thank Petra Roman and Elsy Vareemans for producing the plasmids and Cindy Peleman and Kevin de Jonghe for labeling the single-domain antibodies and performing SPECT/CT imaging.

KEY POINTS

QUESTION: Is detection of LAG-3 using radiolabeled single-domain antibodies predictive of the therapeutic outcome of cancers treated with LAG-3–blocking mAb?

PERTINENT FINDINGS: This preclinical study describes the potential of a radiolabeled single-domain antibody to noninvasively detect the compensatory upregulation of LAG-3 as a consequence of PD-1 blockade in cancer. The combination of PD-1 with LAG-3 blockade was able to significantly reduce tumor growth compared with monotherapy.

IMPLIEDATIONS FOR PATIENT CARE: Single-domain antibodies, as tools to noninvasively monitor the dynamic evolution of LAG-3 expression by TILs, could be exploited to select patients and predict their therapy outcome.

REFERENCES

1. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155.
2. Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. 2018;11:142.
3. O’Donnell JS, Long GV, Scelyor RA, Teng MWL, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81.
4. Andrews LP, Marcusno AE, Drake CG, Vignali DAA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276:80–96.
5. Leocq C, Keyaerts M, Devogucht N, Breckpot K. The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: three time’s a charm. Int J Mol Sci. 2020;22:75.
6. Triebel F, Itsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171:1393–1405.
7. Huang CT, Workman CJ, Fries DJ, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503–513.
8. Kistelov M, Kisielow J, Capoferrer-Sollami G, Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol. 2005;35:2081–2088.
9. Hubbard B, Tourner M, Triebel F. LAG-3 does not define a specific mode of natural killing in human. Immunol Lett. 1998;61:109–112.
10. Andreas S, Piras F, Burdin N, Triebel F. Maturation and activation of dendritic cells induced by lymphocyte activation gene 3 (CD223). J Immunol. 2002;168:3874–3880.
11. Keane C, Law SC, Gould C, et al. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020;4:1367–1377.
12. Baixeras E, Huang C, Miossec C, et al. Characterization of the lymphocyte activation gene 3-encoded protein: a new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176:327–337.
13. Kooi T, Huang L, Pucsek AB, et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015;3:412–423.
14. Xu F, Liu J, Liu D, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 2014;74:3148–3142.
15. Mao X, Ou MT, Kaurapagounder SS, et al. Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353:aah3374.
16. Wang J, Sammaned MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176:334–347.e2.
17. ESMO 2017 congress: 8-12 September 2017—Madrid, Spain. European Society for Medical Oncology website: https://oncologypro.esmo.org/content/download/126251/238526/file/ESMO2017-Congress-Scientific-Meeting-Report.pdf. Accessed April 28, 2021.
18. Broos K, Leocq C, Raes G, Devogucht N, Keyaerts M, Breckpot K. Noninvasive imaging of the PD-1:PDL1 immune checkpoint: embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics. 2018;8:3559–3570.
19. Leocq C, De Vlaeminck Y, Hanssens H, et al. Theranostics in immune-oncology using nanobody derivatives. Theranostics. 2019;9:7772–7791.
20. Teng MWL, Ngsw SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139–2145.
21. Du Y, Jin Y, Sun W, Fang J, Zheng J, Tian J. Advances in molecular imaging of immune checkpoint targets in malignancies: current and future prospect. Eur Radiol. 2019;29:4294–4302.
22. Bensch F, van der Veen L, Lub-de Hooge MN, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852–1858.
23. Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9:4664.
24. Brossat A, Tocezk J, Dumas LS, et al. 89Zr–cAbVCAM1-5 imaging is a sensitive and reproducible tool for the detection of inflamed atherosclerotic lesions in mice. J Nucl Med. 2014;55:1678–1684.
25. Xavier C, Blykers A, Lauoi D, et al. Clinical translation of 89Ga-GLA-anti-PD1/PD-L1 PET/CT imaging of promutagenic macrophages. Mol Imaging Biol. 2019;21:898–906.
26. Keyaerts M, Xavier C, Heemskerk J, et al. Phase I study of 89Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27–33.
27. Xing Y, Chand G, Liu C, et al. Early phase I study of a 89Zr-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer. J Nucl Med. 2019;60:1213–1220.
28. Leocq C, Zeven K, De Vlaeminck Y, et al. Noninvasive imaging of the immune checkpoint LAG-3 using nanobodies, from development to pre-clinical use. Biomolecules. 2019:9:548.
29. Lemaire M, D’Huyvetter M, Lahoutte T, et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia. 2014;28:444–447.
30. Breckpot K, Dullaers M, Bonehill A, et al. Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. J Gene Med. 2003;5:654–667.
31. Yu X, Huang X, Chen X, et al. Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. Mol Biosci. 2019;11:1139–1148.
32. Burova E, Hermann A, Dai J, et al. Preclinical development of the anti-LAG-3 antibody REC37767: characterization and activity in combination with the anti-PD-1 antibody cembilumab in human PD-1xLAG-3-knockin mice. Mol Cancer Ther. 2019;18:2051–2062.
33. Huang R-Y, Francois A, McGray AR, Milloot A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. OncolImmunol. 2016;6: e129451.
34. Huang R-Y, Eppolito C, Lele S, Shrinkant P, Matsuksi J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6:27259–27277.
35. Woo S-R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG3 and PD-1 synergistically regulate T-cell function to promote tumorimal immune escape. Cancer Res. 2012;72:917–927.
36. Harris-Bookman S, Mathios D, Martin AM, et al. Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. Int J Cancer. 2018;143:3201–3208.
37. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating lymphocytes targeting the programmed death-ligand 1 (PD-L1) single-domain antibody for cancer immunotherapy. Mol Biosci. 2016;22:347–350.
38. Lecocq C, De Vlaeminck Y, et al. Novel immune checkpoint LAG-3 using nanobodies, from development to pre-clinical use. Biomolecules. 2019:9:548.